A novel strategy for inducing enhanced mucosal HIV-1 antibody responses in an anti-inflammatory environment

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Wegmann, Frank ^a   Krashias, George ^a   Lühn, Kerstin ^b   Laamanen, Karoliina ^a   Vieira, Sueli ^c   Jeffs, Simon A ^c   Shattock, Robin J ^d   Sattentau, Quentin J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GLYCOPROTEIN GP 140; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; PRO 2000; TOLL LIKE RECEPTOR 4; VIRUS ENVELOPE PROTEIN; GLYCOPROTEIN GP 120; IMMUNOLOGICAL ADJUVANT; NAPHTHALENESULFONIC ACID DERIVATIVE; POLYMER; VIRUS ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL TRANSPORT; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG DOSAGE FORM COMPARISON; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; IN VITRO STUDY; INFLAMMATION; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PROTEIN DEGRADATION; RABBIT; RECEPTOR UPREGULATION; TARGET CELL; TREATMENT OUTCOME; VAGINAL LAVAGE; VIRUS TRANSMISSION; ANIMAL; BIOSYNTHESIS; CHEMISTRY; DRUG COMBINATION; DRUG EFFECT; IMMUNOLOGY; INTRAVAGINAL DRUG ADMINISTRATION;

HUMAN IMMUNODEFICIENCY VIRUS 1; MUS; ORYCTOLAGUS CUNICULUS;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVAGINAL; AIDS VACCINES; ANIMALS; ANTIGENS, VIRAL; DRUG COMBINATIONS; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HUMANS; IMMUNITY, MUCOSAL; INFLAMMATION; MICE; NAPHTHALENESULFONATES; POLYMERS; RABBITS;

EID: 79251588396     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015861     Document Type: Article

References (56)

1. Cohen MS, Hellmann N, Levy JA, DeCock K, Lange J (2008) The spread, treatment, and prevention of HIV-1: evolution of a global pandemic. J Clin Invest 118: 1244-1254.
2. Montefiori D, Sattentau Q, Flores J, Esparza J, Mascola J (2007) Antibody-based HIV-1 vaccines: recent developments and future directions. PLoS Med 4: e348.
3. Karlsson Hedestam GB, Fouchier RA, Phogat S, Burton DR, Sodroski J, et al. (2008) The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol 6: 143-155.
4. Shattock RJ, Haynes BF, Pulendran B, Flores J, Esparza J (2008) Improving defences at the portal of HIV entry: mucosal and innate immunity. PLoS Med 5: e81.
5. Haynes BF, Shattock RJ (2008) Critical issues in mucosal immunity for HIV-1 vaccine development. J Allergy Clin Immunol 122: 3-9; quiz 10-11.
6. Takahashi Y (2007) Memory B cells in systemic and mucosal immune response: implications for successful vaccination. Biosci Biotechnol Biochem 71: 2358-2366.
7. Brandtzaeg P (2007) Induction of secretory immunity and memory at mucosal surfaces. Vaccine 25: 5467-5484.
8. Holmgren J, Czerkinsky C (2005) Mucosal immunity and vaccines. Nat Med 11: S45-53.
9. Wang Y, Abel K, Lantz K, Krieg AM, McChesney MB, et al. (2005) The Tolllike receptor 7 (TLR7) agonist, imiquimod, and the TLR9 agonist, CpG ODN, induce antiviral cytokines and chemokines but do not prevent vaginal transmission of simian immunodeficiency virus when applied intravaginally to rhesus macaques. J Virol 79: 14355-14370.
10. de Jong MA, de Witte L, Oudhoff MJ, Gringhuis SI, Gallay P, et al. (2008) TNFalpha and TLR agonists increase susceptibility to HIV-1 transmission by human Langerhans cells ex vivo. J Clin Invest 118: 3440-3452.
11. Li Q, Estes JD, Schlievert PM, Duan L, Brosnahan AJ, et al. (2009) Glycerol monolaurate prevents mucosal SIV transmission. Nature 458: 1034-1038.
12. Shattock RJ, Moore JP (2003) Inhibiting sexual transmission of HIV-1 infection. Nat Rev Microbiol 1: 25-34.
13. McCormack S, Ramjee G, Kamali A, Rees H, Crook AM, et al. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet 2010: 17.
14. Keller MJ, Zerhouni-Layachi B, Cheshenko N, John M, Hogarty K, et al. (2006) PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial. J Infect Dis 193: 27-35.
15. Mayer KH, Karim SA, Kelly C, Maslankowski L, Rees H, et al. (2003) Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women. AIDS 17: 321-329.
16. Lacey CJ, Wright A, Weber JN, Profy AT (2006) Direct measurement of in-vivo vaginal microbicide levels of PRO 2000 achieved in a human safety study. AIDS 20: 1027-1030.
17. Keller MJ, Guzman E, Hazrati E, Kasowitz A, Cheshenko N, et al. (2007) PRO 2000 elicits a decline in genital tract immune mediators without compromising intrinsic antimicrobial activity. AIDS 21: 467-476.
18. Moulard M, Lortat-Jacob H, Mondor I, Roca G, Wyatt R, et al. (2000) Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120. J Virol 74: 1948-1960.
19. Vives RR, Imberty A, Sattentau QJ, Lortat-Jacob H (2005) Heparan sulfate targets the HIV-1 envelope glycoprotein gp120 coreceptor binding site. J Biol Chem 280: 21353-21357.
20. Scordi-Bello IA, Mosoian A, He C, Chen Y, Cheng Y, et al. (2005) Candidate sulfonated and sulfated topical microbicides: comparison of anti-human immunodeficiency virus activities and mechanisms of action. Antimicrob Agents Chemother 49: 3607-3615.
21. Hartley O, Klasse PJ, Sattentau QJ, Moore JP (2005) V3: HIV's switch-hitter. AIDS Res Hum Retroviruses 21: 171-189.
22. Labrijn AF, Poignard P, Raja A, Zwick MB, Delgado K, et al. (2003) Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol 77: 10557-10565.
23. Seidah NG, Chretien M (1997) Eukaryotic protein processing: endoproteolysis of precursor proteins. Curr Opin Biotechnol 8: 602-607.
24. Zhou T, Xu L, Dey B, Hessell AJ, Van Ryk D, et al. (2007) Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445: 732-737.
25. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, et al. (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326: 285-289.
26. Kim M, Qiao Z-S, Montefiori DC, Haynes BF, Reinherz EL, et al. (2005) Comparison of HIV Type 1 ADA gp120 Monomers versus gp140 Trimers as Immunogens for the Induction of Neutralizing Antibodies. AIDS Research and Human Retroviruses 21: 58.
27. Beddows S, Franti M, Dey AK, Kirschner M, Iyer SPN, et al. (2007) A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120. Virology 360: 329-340.
28. Forsell MN, Schief WR, Wyatt RT (2009) Immunogenicity of HIV-1 envelope glycoprotein oligomers. Curr Opin HIV AIDS 4: 380-387.
29. McCutchan FE (2006) Global epidemiology of HIV. J Med Virol 78: S7-S12.
30. Veazey RS, Shattock RJ, Pope M, Kirijan JC, Jones J, et al. (2003) Prevention ofvirus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med 9: 343-346.
31. Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, et al. (1994) Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266: 1024-1027.
32. Russell MW (2002) Immunization for protection of the reproductive tract: a review. Am J Reprod Immunol 47: 265-268.
33. Black CA, Rohan LC, Cost M, Watkins SC, Draviam R, et al. (2000) Vaginal mucosa serves as an inductive site for tolerance. J Immunol 165: 5077-5083.
34. Mascola JR, D'Souza P, Gilbert P, Hahn BH, Haigwood NL, et al. (2005) Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J Virol 79: 10103-10107.
35. Neutra MR, Kozlowski PA (2006) Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 6: 148-158.
36. Imaoka K, Miller CJ, Kubota M, McChesney MB, Lohman B, et al. (1998) Nasal immunization of nonhuman primates with simian immunodeficiency virus p55gag and cholera toxin adjuvant induces Th1/Th2 help for virus-specific immune responses in reproductive tissues. J Immunol 161: 5952-5958.
37. Johansson EL, Rask C, Fredriksson M, Eriksson K, Czerkinsky C, et al. (1998) Antibodies and antibody-secreting cells in the female genital tract after vaginal or intranasal immunization with cholera toxin B subunit or conjugates. Infect Immun 66: 514-520.
38. Boussif O, Lezoualc'h F, Zanta MA, Mergny MD, Scherman D, et al. (1995) A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci U S A 92: 7297-7301.
39. Lungwitz U, Breunig M, Blunk T, Gopferich A (2005) Polyethylenimine-based non-viral gene delivery systems. Eur J Pharm Biopharm 60: 247-266.
40. Yip HC, Karulin AY, Tary-Lehmann M, Hesse MD, Radeke H, et al. (1999) Adjuvant-guided type-1 and type-2 immunity: infectious/noninfectious dichotomy defines the class of response. J Immunol 162: 3942-3949.
41. Campbell GR, Spector SA (2008) CCL2 increases X4-tropic HIV-1 entry into resting CD4+ T cells. J Biol Chem 283: 30745-30753.
42. Ansari AW, Heiken H, Moenkemeyer M, Schmidt RE (2007) Dichotomous effects of C-C chemokines in HIV-1 pathogenesis. Immunol Lett 110: 1-5.
43. Spirig R, van Kooten C, Obregon C, Nicod L, Daha M, et al. (2008) The complement inhibitor low molecular weight dextran sulfate prevents TLR4-induced phenotypic and functional maturation of human dendritic cells. J Immunol 181: 878-890.
44. Cranage MP, Fraser CA, Stevens Z, Huting J, Chang M, et al. (2009) Repeated vaginal administration of trimeric HIV-1 clade C gp140 induces serum and mucosal antibody responses. Mucosal Immunol 3: 57-68.
45. Brandtzaeg P (1997) Mucosal immunity in the female genital tract. J Reprod Immunol 36: 23-50.
46. Iwasaki A (2010) Antiviral immune responses in the genital tract: clues for vaccines. Nat Rev Immunol 10: 699-711. Epub 2010 Sep 2010.
47. Seaman MS, Leblanc DF, Grandpre LE, Bartman MT, Montefiori DC, et al. (2007) Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multi-clade HIV-1 envelope immunogens. Virology 367: 175-186.
48. Hessell AJ, Poignard P, Hunter M, Hangartner L, Tehrani DM, et al. (2009) Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 15: 951-954. Epub 2009 Jun 2007.
49. Teleshova N, Chang T, Profy A, Klotman ME (2008) Inhibitory effect of PRO 2000, a candidate microbicide, on dendritic cell-mediated human immunodeficiency virus transfer. Antimicrob Agents Chemother 52: 1751-1758. Epub 2008 Mar 1710.
50. Zariffard MR, Novak RM, Lurain N, Sha BE, Graham P, et al. (2005) Induction of tumor necrosis factor- alpha secretion and toll-like receptor 2 and 4 mRNA expression by genital mucosal fluids from women with bacterial vaginosis. J Infect Dis 191: 1913-1921.
51. Roehr B (2009) Microbicide offers no protection against HIV infection. BMJ 18.
52. Rodenburg CM, Li Y, Trask SA, Chen Y, Decker J, et al. (2001) Near full-length clones and reference sequences for subtype C isolates of HIV type 1 from three different continents. AIDS Res Hum Retroviruses 17: 161-168.
53. Su L, Graf M, Zhang Y, von Briesen H, Xing H, et al. (2000) Characterization of a virtually full-length human immunodeficiency virus type 1 genome of a prevalent intersubtype (C/B') recombinant strain in China. J Virol 74: 11367-11376.
54. Montefiori DC (2005) Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr Protoc Immunol 12: 11.
55. Zhu Y, Ho B, Ding JL (2003) Sequence and structural diversity in endotoxinbinding dodecapeptides. Biochim Biophys Acta 1611: 234-242.
56. Wittig I, Braun HP, Schagger H (2006) Blue native PAGE. Nat Protoc 1: 418-428.